By: Leah Lawrence From: medpagetoday.com The challenge may have more to do with the assessment of the patient’s overall health The median age at breast cancer diagnosis is 63, with about 20% of new cases occurring in women older than 75. HER2-positive breast cancer is less common in older women compared with younger women, but still occurs in about 10% …
Tumor marker may help overcome endocrine treatment-resistant breast cancer
Source: Sanford Burnham Prebys Medical Discovery Institute From: eurekalert.org Testing may identify patients who benefit from early HER2 targeted therapy A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to …
Tumor marker may help overcome endocrine treatment-resistant breast cancer
By: Sanford Burnham Prebys Medical Discovery Institute From: medicalxpress.com A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes …
Potential new treatment strategy for breast cancer cells that have spread to the brain
Source: Massachusetts General Hospital From: eurekalert.org New research reveals that when breast cancer cells spread to the brain, they must boost production of fatty acids, the building blocks of fat, in order to survive there. The work, which is published in Nature Cancer and was led by investigators at Massachusetts General Hospital (MGH) and the Koch Institute of the Massachusetts …
Greenwich LifeSciences Presents Immune Response Phase IIb Poster
From: businesswire.com Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a …
A new co-driver in breast cancer
Source: University of Cincinnati From: eurekalert.org Cooperation is generally a good thing — working together to reach a goal. But in the case of cancer, it can be detrimental. University of Cincinnati researchers have discovered that cooperation between two key genes drive cancer growth, spread and treatment resistance in one particularly aggressive type of breast cancer. The good news is, …
Researchers found that stopping cell recycling in cancer cells could help treat a very aggressive form of breast cancer
Source: University of Cincinnati From: sciencedaily.com Targeting and changing autophagy, otherwise known as cell recycling, has been linked to helping control or diminish certain cancers. Now, researchers have shown that completely halting this process in a very aggressive form of breast cancer may improve outcomes for patients one day. Recycling cans and bottles is a good practice. It helps keep …
SORLA protein promotes the growth of breast cancer brain metastasis
Source: University of Turku From: news-medical.net SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. …
Alpha-TEA helps with breast cancer
By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
Source: GT Biopharma, Inc. From: prnewswire.com GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer …